The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study.
Clinical scales
Curcumin
Dietary supplement
Parkinson disease
Protein misfolding
Skin biopsy
α-Synuclein
Journal
Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R
Informations de publication
Date de publication:
20 06 2022
20 06 2022
Historique:
pubmed:
14
5
2022
medline:
23
6
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
There are currently no standardized therapies for Parkinson disease (PD). Curcumin shows anti-amyloidogenic properties in vitro and may be a promising treatment for PD. We evaluated the effects of curcumin supplementation on clinical scales and misfolded, phosphorylated α-synuclein (p-syn) accumulation in skin biopsies in 19 PD patients who received curcumin supplementation for 12 months and 14 PD patients to treated with curcumin. The patients underwent autonomic (COMPASS-31), motor (MDS-UPDRS and H&Y) and nonmotor (NMSS) questionnaires and skin biopsies to evaluate clinical involvement and p-syn load in skin nerves at the beginning and the end of study. Curcumin and curcuminoid levels were assayed in plasma and CSF. Supplemented patients showed detectable CSF curcuminoid levels that were lower than those in plasma. They showed a decrease of COMPASS-31 and NMSS scores, and a slight p-syn load decrease versus untreated patients who displayed a worsening of these parameters despite increased levodopa doses. Multiple regression models showed a significant effect of curcumin supplementation in decreasing the worsening of the clinical parameters and p-syn load at after curcumin treatment. These data suggest that curcumin can cross the blood-brain barrier, that it is effective in ameliorating clinical parameters and that it shows a tendency to decrease skin p-syn accumulation in PD patients.
Identifiants
pubmed: 35556131
pii: 6585246
doi: 10.1093/jnen/nlac034
pmc: PMC9210322
doi:
Substances chimiques
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-552Informations de copyright
© 2022 American Association of Neuropathologists, Inc. All rights reserved.
Références
J Neuropathol Exp Neurol. 2018 Oct 1;77(10):942-949
pubmed: 30137426
Adv Exp Med Biol. 2007;595:197-212
pubmed: 17569212
Neurology. 2013 Feb 19;80(8):725-32
pubmed: 23390175
Acta Neuropathol. 2014 Jul;128(1):99-109
pubmed: 24788821
Acta Neuropathol. 2008 Apr;115(4):479-89
pubmed: 18189141
Parkinsonism Relat Disord. 2017 Jan;34:38-42
pubmed: 28029554
Curr Pharm Des. 2013;19(11):2011-31
pubmed: 23116310
Biofactors. 2021 Jul;47(4):570-586
pubmed: 33893674
Lancet Neurol. 2015 Aug;14(8):855-866
pubmed: 26050140
Clin Auton Res. 2019 Dec;29(6):577-585
pubmed: 30506233
Ann Clin Transl Neurol. 2018 Oct 14;5(11):1394-1407
pubmed: 30480033
PLoS One. 2015 Jun 02;10(6):e0128510
pubmed: 26035833
J Biol Chem. 2012 Mar 16;287(12):9193-9
pubmed: 22267729
JAMA Neurol. 2020 Sep 28;:
pubmed: 32986090
Neurology. 2021 May 18;96(20):e2513-e2524
pubmed: 33837116
Eur J Neurol. 2019 Oct;26(10):1245-1251
pubmed: 30770596
Acta Neuropathol. 2017 Apr;133(4):535-545
pubmed: 28180961
J Pharmacol Exp Ther. 2008 Jul;326(1):196-208
pubmed: 18417733
J Neural Transm (Vienna). 2003 May;110(5):517-36
pubmed: 12721813
Neurol Sci. 2015 Oct;36(10):1897-902
pubmed: 26081007
Transl Neurodegener. 2012 Aug 20;1(1):16
pubmed: 23210631
Alzheimers Res Ther. 2012 Oct 29;4(5):43
pubmed: 23107780
Neurology. 2007 Jan 30;68(5):384-6
pubmed: 17082464
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Mov Disord. 2019 Oct;34(10):1452-1463
pubmed: 31322768
J Nat Prod. 2011 Apr 25;74(4):664-9
pubmed: 21413691
Neurology. 2017 May 30;88(22):2128-2131
pubmed: 28468843
J Clin Pharmacol. 2017 Feb;57(2):185-193
pubmed: 27503249
J Neuropathol Exp Neurol. 2017 May 1;76(5):384-389
pubmed: 28402459
Neurology. 2017 Jul 25;89(4):318-326
pubmed: 28667178